Blueprint Medicines (NASDAQ:BPMC) Bolsa

BLUEPRINT MEDICINES CORP

Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Shanghai,,China,-,June,29,,2023:,Saic,Roewe,Feifan,F7

Tech

BPMC

CRDO

PSTV

SAIC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: CPB, SAIC, PSTV, BPMC y CRDO.

5 acciones en el foco este lunes: CPB, SAIC, PSTV, BPMC y CRDO

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

Morgan Stanley analyst Judah Frommer maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Equal-Weight and raises the price target from $102 to $129.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $129

UBS analyst David Dai maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Neutral and raises the price target from $88 to $129.

UBS Maintains Neutral on Blueprint Medicines, Raises Price Target to $129

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) from Neutral to Buy and raised the price target from $22 to $38. AnaptysBio shares closed at $23.52 on Tuesday. <a href="https://www.benzinga.com/quote/ANAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst David Anderson upgraded Cactus, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) from Equal-Weight to Overweight and raised the price target from $51 to $54. Cactus shares closed at $44.11 on Tuesday. <a href="https://www.benzinga.com/quote/WHD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Cenk Orcan upgraded the rating for Embraer S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) from Hold to Buy and raises the price target from $45 to $57. Embraer shares closed at $45.99 on Tuesday. <a href="https://www.benzinga.com/quote/ERJ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst David Lebowitz upgraded Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raised the price target from $83 to $129. Blueprint Medicines shares closed at $127.60 on Tuesday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Karl Keirstead upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raised the price target from $210 to $265. Snowflake shares closed at $209.18 on Tuesday. <a href="https://www.benzinga.com/quote/snow/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SNOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SNOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png" alt="" class="wp-image-938280" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04093653/image-49.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Markets

Trading Ideas

ANAB

Embraer-Empresa Brasileira De Aeronautica

SNOW

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raises the price target from $83 to $129.

Citigroup Upgrades Blueprint Medicines to Neutral, Raises Price Target to $129

JMP Securities analyst Reni Benjamin downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Market Outperform to Market Perform.

Downgrades

JMP Securities Downgrades Blueprint Medicines to Market Perform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Andy Chen downgraded the rating for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Peer Perform. Blueprint Medicines shares closed at $127.79 on Monday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Chris LaFemina downgraded Rio Tinto Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) from Buy to Hold. Rio Tinto shares closed at $59.58 on Monday. <a href="https://www.benzinga.com/quote/RIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Cory Carpenter downgraded the rating for Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) from Neutral to Underweight and maintained the price target of $5. Bumble shares closed at $5.74 on Monday. <a href="https://www.benzinga.com/quote/BMBL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Simon Coles downgraded ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) from Overweight to Equal-Weight. ASML shares closed at $746.53 on Monday. <a href="https://www.benzinga.com/quote/ASML/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Jackie Przybylowski downgraded the rating for MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) from Outperform to Market Perform but raised the price target from $11 to $12.25. MAC Copper shares closed at $12.24 on Monday. <a href="https://www.benzinga.com/quote/MTAL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ASML stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-1024x588.png" alt="" class="wp-image-936720" style="width:666px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03091853/image-31.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

ASML

BMBL

MTAL

This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>RBC Capital analyst Brad Erickson initiated coverage on Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Sector Perform rating and announced a price target of $125. Reddit shares closed at $112.11 on Monday. <a href="https://www.benzinga.com/quote/rddt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Jason Haas initiated coverage on ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) with an Equal-Weight rating and announced a price target of $56. ASGN shares closed at $51.72 on Monday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Vanvliet initiated coverage on Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with an Overweight rating and announced a price target of $325. Salesforce shares closed at $261.62 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Vanvliet initiated coverage on Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with an Overweight rating and announced a price target of $125. Agilysys shares closed at $108.20 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Alexander Pearce initiated coverage on Uranium Energy Corp.  (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) with an Outperform rating and announced a price target of $7.75. Uranium Energy shares closed at $5.69 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying RDDT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-1024x566.png" alt="" class="wp-image-936677" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03090021/image-30.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

AGYS

ASGN

PINS

RDDT

This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Stephens &amp; Co. analyst Sudan Loganathan downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Equal-Weight and lowers the price target from $150 to $135.

Stephens & Co. Downgrades Blueprint Medicines to Equal-Weight, Lowers Price Target to $135

Wolfe Research analyst Andy Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Peer Perform.

Wolfe Research Downgrades Blueprint Medicines to Peer Perform

Scotiabank analyst Louise Chen downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sector Outperform to Sector Perform and announces $135 price target.

Scotiabank Downgrades Blueprint Medicines to Sector Perform, Announces $135 Price Target

JP Morgan analyst Brian Cheng downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Overweight to Neutral and lowers the price target from $130 to $129.

JP Morgan Downgrades Blueprint Medicines to Neutral, Lowers Price Target to $129

U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Monday.
Shares of Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) rose sharply during Monday's session after the company <a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data">released ORIGIN Phase 3 trial data.</a>
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36.
Vera Therapeutics shares jumped 56.6% to $29.67 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) surged 44.8% to $9.89 after the company announced a 250MW AI data center lease with CoreWeave.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) climbed 33.3% to $39.53 after the company announced clinical data for its Phase 1 Healthy volunteer study of KT-621.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 26.2% to $127.93 after the company announced that Sanofi will acquire them for $9.5 billion.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) gained 23.2% to $7.18 after Trump said he would double their tariffs to 50%.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) rose 22% to $18.89 after Trump said he would double their tariffs to 50%.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) gained 18.2% to $17.64 after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) jumped 16.4% to $10.30.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 14.1% to $62.95 after the company introduced its fuses program for precision-based medicine and xM for advanced cancer treatment response monitoring.</li>
<li>First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) rose 10.6% to $6.83.</li>
<li>Steel Dynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) surged 10.5% to $135.93. Shares of steel and aluminum stocks traded higher after Trump said he would double their tariffs to 50%.</li>
<li>Hecla Mining Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>) gained 10.4% to $5.67.</li>
<li>Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) gained 10% to $120.20. BMO Capital analyst Katja Jancic upgraded Nucor from Market Perform to Outperform and raised the price target from $140 to $145.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 6.2% to $2.8250. ImmunityBio received FDA expanded access authorization for the treatment of Lymphopenia with ANKTIVA in patients with solid tumors</li>
<li>Eldorado Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGO#NYSE">EGO</a>) rose 6.1% to $21.32.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

APLD

CENX

IBRX

KYMR

LQDA

RGNX

STLD

VERA

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Truist Securities raised Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $89 to $100. Truist Securities analyst Scot Ciccarelli maintained a Buy rating. Dollar Tree shares closed at $90.26 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">view this stock</a>.</li>
<li>Keybanc slashed the price target for UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from $450 to $400. Keybanc analyst Matthew Gillmor maintained an Overweight rating. UnitedHealth shares closed at $301.91 on Friday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) price target from $74 to $79. Raymond James analyst John Davis maintained an Outperform rating. Block shares closed at $61.75 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/xyz/analyst-ratings">view this stock</a>.</li>
<li>Wedbush increased the price target for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from $128 to $129. Wedbush analyst David Nierengarten downgraded the stock from Outperform to Neutral. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/bpmc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho increased the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $15 to $18. Mizuho analyst Maheep Mandloi maintained a Neutral rating. SolarEdge Technologies shares closed at $17.86 on Friday. <a href="https://www.benzinga.com/quote/sedg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS raised SPX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) price target from $160 to $182. UBS analyst Damian Karas upgraded the stock from Neutral to Buy. SPX Technologies shares settled at $152.09 on Friday. <a href="https://www.benzinga.com/quote/spxc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) price target from $132 to $135. Morgan Stanley analyst Devin McDermott maintained an Equal-Weight rating. EOG Resources shares closed at $108.57 on Friday. <a href="https://www.benzinga.com/quote/eog/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Rollins, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) price target from $55 to $65. Jefferies analyst Stephanie Moore upgraded the stock from Hold to Buy. Rollins shares closed at $57.24 on Friday.  <a href="https://www.benzinga.com/quote/rol/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased the price target for The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from $185 to $260. B of A Securities analyst Ronald Epstein upgraded the stock from Neutral to Buy. Boeing shares settled at $207.29 on Friday. <a href="https://www.benzinga.com/quote/ba/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) price target from $45 to $65. Goldman Sachs analyst Jordan Alliger upgraded the stock from Neutral to Buy. Knight-Swift Transportation shares closed at $44.32 on Friday. <a href="https://www.benzinga.com/quote/knx/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying BA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png" alt="" class="wp-image-935238" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02093559/image-11.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

DLTR

SEDG

SPXC

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Jordan Alliger downgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Buy to Neutral and maintained the price target of $263. Union Pacific shares closed at $221.66 on Friday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Frank Louthan downgraded the rating for Rackspace Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) from Outperform to Market Perform. Rackspace Technology shares closed at $1.14 on Friday. <a href="https://www.benzinga.com/quote/RXT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Andrew Mok downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and slashed the price target from $84 to $65. Centene shares closed at $56.44 on Friday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>eedham analyst Ami Fadia downgraded the rating for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintained the price target of $130. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Paul Fremont downgraded NorthWestern Energy Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and cut the price target from $57.5 to $56. NorthWestern Energy shares closed at $55.33 on Friday. <a href="https://www.benzinga.com/quote/NWE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying UNP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png" alt="" class="wp-image-935215" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wedbush analyst David Nierengarten downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Neutral and raises the price target from $128 to $129.

Wedbush Downgrades Blueprint Medicines to Neutral, Raises Price Target to $129

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $130.12, along with a high estimate of $150.00 and a low estimate of $100.00. Marking an increase of 0.22%, the current average surpasses the previous average price target of $129.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869252_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Blueprint Medicines's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Blueprint Medicines's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Discovering Blueprint Medicines: A Closer Look</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
<h3>Blueprint Medicines: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 55.45%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE excels beyond industry benchmarks, reaching 0.15%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's ROA stands out, surpassing industry averages. With an impressive ROA of 0.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Blueprint Medicines's debt-to-equity ratio stands notably higher than the industry average, reaching 1.36. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Blueprint Medicines's Future

Needham analyst Ami Fadia downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintains the price target from $130 to $130.

Needham Downgrades Blueprint Medicines to Hold, Maintains Price Target to $130

WIIM

Blueprint Medicines shares are trading higher after the company announced that Sanofi will acquire them for $9.5 billion.

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>).
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">early-stage immunology pipeline</a>.
Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM &amp; ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs.
The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/41987123/blood-cancer-focused-blueprint-medicines-could-be-attractive-target-for-partnerships-analyst-initiates-with-around-30-upside" rel="noreferrer noopener">Blood Cancer-Focused Blueprint Medicines Could Be &#8216;Attractive Target For Partnerships&#8217;: Analyst</a>
Sanofi will pay&nbsp;$129.00&nbsp;per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45714358/sanofi-to-acquire-blueprint-medicines-expanding-portfolio-in-rare-immunological-disease-and-adding" rel="noreferrer noopener">approximately&nbsp;$9.1 billion</a>.
Blueprint shareholders will also receive one contingent value right (CVR), which entitles the holder to two potential milestone payments of&nbsp;$2&nbsp;and&nbsp;$4&nbsp;per CVR to achieve future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, represents approximately&nbsp;$9.5 billion&nbsp;on a fully diluted basis.
Paul Hudson, CEO of Sanofi, said, &#8220;The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios&#8230;It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.&#8221;&nbsp;
Ayvakit achieved net revenues of&nbsp;$479 million&nbsp;in 2024 and nearly&nbsp;$150 million&nbsp;in Q1 2025, representing year-on-year growth of more than 60% over Q1 2024.
Sanofi currently expects to complete the acquisition in the third quarter of 2025. The acquisition will not significantly impact Sanofi&#8217;s financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
In another development, Sanofi exercised its option to exclusively license Nurix Therapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) STAT6 program on Monday, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.
STAT6 (signal transducer and activator of transcription 6) plays a central role in type 2 inflammation, which drives diseases such as atopic dermatitis and asthma.
Under its 2019 collaboration agreement, Nurix will receive a $15 million license extension fee from Sanofi, bringing the total amount received under this <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717764/sanofi-exercises-license-extension-option-to-nurixs-stat6-program" rel="noreferrer noopener">collaboration to $127 million</a>.
Nurix is eligible for an additional $465 million in development, regulatory, and commercial milestones associated with the STAT6 program and potential future royalties and retains an option to co-develop and co-promote in the U.S.
Price Action: SNY stock is trading lower by 0.73% to $49.01, BPMC stock is trading higher by 26.8% to $128.50, and NRIX stock is trading lower by 0.28% to $10.60 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Drop After Trump Renews Trade Tensions</a></li>
</ul>
Photo by HJBC via Shutterstock

Biotech

Health Care

Contracts

Movers

General

NRIX

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Shares of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose sharply in <a href="https://www.benzinga.com/quote/BPMC/news">today's pre-market trading</a>.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines for $9.5 billion.
Blueprint Medicines shares jumped 26.9% to $128.62 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares jumped 199% to $14.74 in pre-market trading after the company reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of Chronic Rhinosinusitis (CRS).</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) rose 93.2% to $4.81 in pre-market trading.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) surged 69% to $32.02 in pre-market trading after the company said Atacicept ORIGIN Phase 3 trial met primary endpoint of reduction in UPCR for IgAN treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) jumped 68.5% to $0.47 in pre-market trading after gaining 13% on Friday.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) surged 51.4% to $9.20 in pre-market trading after jumping 485% on Friday.</li>
<li>Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) gained 37.3% to $13.29 in pre-market trading after falling 5% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) climbed 27.7% to $1.6990 in pre-market trading after jumping 24% on Friday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rose 25.6% to $7.32 in pre-market trading.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 14.1% to $109.32 in pre-market trading. BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 23.2% to $3.77 in pre-market trading. ReShape Lifesciences entered into equity distribution agreement relating to sale of up to $9.7 million of shares of common stock.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 22.6% to $0.7500 in pre-market trading after the company announced suspension of Nasdaq trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 20.2% to $0.8300 in pre-market trading after gaining 8% on Friday.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) fell 17.9% to $0.8788 in pre-market trading after the company announced a proposed public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 16.4% to $0.1629 in today's pre-market trading. Super League Enterprise, on Friday, announced a registered direct offering.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 16% to $1.68 in pre-market trading. TIAN RUIXIANG shares gained 8% on Friday after the company announced plans to buy Ucare for $150 million in an all-stock deal.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 MILLION.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ASTL

BMGL

BNAI

BNTX

BSII

CLEU

FAAS

LOGC

LUCD

LYRA

RSLS

SBET

SLXN

TIRX

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

Press Releases

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Earnings

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders

Legal

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders

Comments

Blueprint Medicines

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL